Ancient herbal tonic put to the test for male fertility
NCT ID NCT07270146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 trial tested whether Guilu Erxian Oral Liquid, a traditional Chinese herbal remedy, can improve sperm count and movement in men with mild to moderate low sperm count or poor sperm motility. The study enrolled 360 married men aged 22 to 40 who also had a diagnosis of kidney essence deficiency. Participants received either the herbal liquid or a standard comparator, and researchers measured changes in total motile sperm count and other semen parameters.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Guilu Erxian Oral Liquid (a traditional Chinese herbal remedy)
- What this could lead to
- If it works, this could offer a treatment option for men with low sperm count or poor sperm movement related to kidney essence deficiency.
- What could go wrong
- This is a Phase 4 trial, but results are not yet published. The condition is subjective and the herbal remedy may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
360 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
Feb 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 40 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Married men aged 22 to 40; 2. Meet the diagnostic criteria of male infertility; 3. Meet the diagnostic criteria for mild and moderate oligozoospermia, asthenospermia and oligoasthenospermia; 4. Meet the TCM syndrome differentiation standard of Shen (kidney) essence deficiency syndrome; 5. Sign the informed consent form voluntarily. Exclusion Criteria: 1. Infertility due to chromosome abnormalities (such as Roche heterotopia, Y chromosome microdeletion, etc.); 2. Varicocele or cryptorchidism; 3. Diseases affecting semen quality such as orchitis, epididymitis, mycoplasma and chlamydia infection; 4. Anejaculation, retrograde ejaculation and other sexual dysfunction; 5. Severe liver and kidney dysfunction (alanine aminotransferase (ALT)\>1.5 × ULN, aspartate aminotransferase (AST)\>1.5 × ULN, blood urea nitrogen (BUN)\>2 × ULN, Cr\>1 × ULN), disease of cardiovascular and cerebrovascular system, disease of hematopoietic system; 6. Hypertension (systolic blood pressure \> 160 mmHg and / or diastolic blood pressure \> 100 mmHg) or diabetes (fasting blood glucose \> 7mmol / L) with poor drug control; 7. Serious mental illness, accompanied by mental disorder or loss of self-care ability; 8. Those who are allergic to the test drug; 9. Those who have long term bad habits such as smoking and drinking, which may affect fertility, or those who cannot ban smoking and drinking during the test, the specific criteria are as follows: ①History of smoking: Those who have smoked more than 5 cigarettes per day in the past 6 months; ②History of drinking: in the past 6 months, the average daily consumption of alcohol exceeded the following standards: 570 ml of beer, 200 ml of wine or 60 ml of spirit, each containing about 20 g of alcohol; 10. Those who have been unable to take the test drug in the past or have intolerable adverse reactions; 11. Those who used drugs to improve or affect sperm concentration or motility 1 month before screening; 12. Those who have participated in other clinical trials within 3 months before screening; 13. According to the judgment of the investigator, there are other persons who are not suitable to participate in this clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mild and moderate oligozoospermia asthenospermia or oligoasthenospermia and the syndrome differentiation type is shen (kidney) essence deficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xi Yuan Hospital of China Academy of Chinese Medical Sciences
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seaweed supplement could boost sperm quality in infertile men
- Walnuts may boost sperm quality, study finds
- New sperm-boosting method tested in 300 men
- Cold soup, hot sperm: gazpacho diet tested for male fertility
- Could probiotics boost sperm quality? new trial aims to find out
- New injection aims to boost sperm count – first human safety tests underway